Vimarsana
Biggest News Aggregation in the World

Debayan Ghosh News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Debayan Ghosh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Debayan Ghosh Today - Breaking & Trending Today

'CCTV Footage Destructed, Lapses In Arrest' : Calcutta HC Orders ₹2 Lakh Compensation For Man Allegedly Implicated 'Falsely' Under NDPS Act - Vimarsana News

'CCTV Footage Destructed, Lapses In Arrest' : Calcutta HC Orders ₹2 Lakh Compensation For Man Allegedly Implicated 'Falsely' Under NDPS Act

The Calcutta High Court today ordered the state government to provide Rs. 2 Lakh as compensation, to the family members of an accused (allegedly implicated falsely for offence under the NDPS Act)...

Source: livelaw.in
Dubai-based company to set up Biotech Park in Tripura - Vimarsana News

Dubai-based company to set up Biotech Park in Tripura

Uniindia: Agartala, April 6 (UNI) The Science 20 Conference of G 20 held at Agartala bears fruit as the pioneer of Biotech Park in Dubai has expressed its interest to set up the first specialized Bio-technology Park of Northeast in Tripura for catering to its clients across South Asian countries.

Epygen Biotech Announces Funding from India Government for - Vimarsana News

Epygen Biotech Announces Funding from India Government for

India’s Department of Biotechnology, Government of India to support scale up and production of cGMP batches of SARS-CoV-2 antigenFunding earmarked to...

Govt funds Epygen Biotech, to make affordable COVID-19 vaccine for less than Rs 150 - Vimarsana News

Govt funds Epygen Biotech, to make affordable COVID-19 vaccine for less than Rs 150

Govt funds Epygen Biotech, to make affordable COVID-19 vaccine for less than Rs 150

COVID-19: Epygen Biotech receives funding from govt for new affordable vaccine - Vimarsana News

COVID-19: Epygen Biotech receives funding from govt for new affordable vaccine

With an anticipated price point of less than Rs 150 per dose, this will be the first time an Indian company will be able to adopt the highly productive C1-cell protein production platform.